<div id="readability-page-1">01:56 PM EST, 12/16/2025 (MT Newswires) -- Quipt Home Medical ( QIPT ) price target has been cut to C$5.10, from C$6.70 with a sell rating (previously buy), at Stifel Canada,Stifel noted Quipt is being acquired by private equity managers Kingswood Capital and Forager Capital for US$260 million (US$3.65/sh), representing a 40% premium to the Dec. 12 close price (US$2.61) and 54% to the 30-day VWAP, writes analyst Justin Keywood.It also noted Forager has a 9.7% stake in Quipt and has engaged with the board three times since January, soliciting offers ranging from US$3.10-US$3.90/share. The consideration is &#34;fair&#34;, given the business is sub-scale with a current DOJ billing investigation, as certain other industry headwinds persist, adds Keywood.&#34;Although, a superior bid could emerge with only a US$250k break-fee, we believe the long duration M&amp;A process has been robust as other undervalued healthcare opportunities exist within our coverage and better use of capital.&#34;Price: 4.81, Change: +0.16, Percent Change: +3.44 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

QIPT

Stifel Canada 將 Quipt Home Medical 的目標股價從 6.70 加元下調至 5.10 加元，此次調整是在其被 Kingswood Capital 和 Forager Capital 以 2.6 億美元收購之後。收購價格較 12 月 12 日的收盤價溢價 40%。分析師 Justin Keywood 指出，儘管面臨行業逆風和美國司法部的調查，這筆收購仍然是公平的。可能會出現更高的出價，但併購過程被認為是穩健的

在收購公告發布後，Stifel Canada 將 Quipt Home Medical 的目標價下調至 5.10 美元